Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Presenter: Hirotoshi Watanabe

September 28, 2019

Presentation TCT 2019

TICAKOREA: A Randomized Trial of Ticagrelor vs. Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management

Presenter: Duk-Woo Park

September 28, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Advertisement

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

TICAKOREA: A Randomized Trial of Ticagrelor vs. Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content